Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2023-11-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司关于公司参与第九批全国药品集中采购拟中标的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing SL Pharmaceutical Co., Ltd. regarding the company's participation and proposed winning in the ninth batch of national centralized drug procurement. It details the products involved, their prices, sales impact, and potential future effects on the company. The document is relatively short (1576 characters) and serves as an announcement of a business event related to procurement results rather than a financial report or detailed management discussion. It does not contain financial statements, audit information, or regulatory certifications. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category about business operations and procurement results, which aligns with Regulatory Filings (RNS).
2023-11-07 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled "北京双鹭药业股份有限公司2023 年第三季度报告" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2023 Third Quarter Report." It contains detailed financial data including balance sheets, income statements, cash flow statements, and notes on non-recurring gains and losses. The report covers the third quarter of 2023, indicating it is a quarterly financial report. It explicitly states that the report is unaudited and includes comprehensive financial figures and analysis for the quarter. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is not a brief announcement or a certification, but a full quarterly report with detailed financials and management commentary. Therefore, the correct classification is IR with high confidence. 9M 2023
2023-10-25 Chinese
北京双鹭药业股份有限公司关于获得化学药品一类新药MBT-1608药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Beijing SL Pharmaceutical Co., Ltd. regarding the receipt of a clinical trial approval notice for a new chemical drug MBT-1608 from the National Medical Products Administration. It details the drug's basic information, patent status, pharmacological properties, and the impact on the company. The document is short (1216 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed clinical study. It does not contain financial data, management changes, voting results, or other report types. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2023-10-19 Chinese
北京双鹭药业股份有限公司关于公司股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding abnormal stock price fluctuations over several trading days. It includes explanations about the company's stock price movements, confirmation of no undisclosed material information, and a risk warning to investors. It also mentions the upcoming disclosure of the 2023 third quarter report but does not contain any actual financial data or detailed financial statements. The document is relatively short (1822 characters) and serves as a regulatory disclosure about stock trading activity rather than a financial report or earnings release. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-10-16 Chinese
北京双鹭药业股份有限公司关于公司股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Shuanglu Pharmaceutical Co., Ltd. regarding abnormal stock price fluctuations over three consecutive trading days. It includes explanations about the situation, confirmation of no undisclosed material information, and risk warnings to investors. The document is short (1045 characters) and focuses on stock trading irregularities and compliance with disclosure rules. It does not contain financial statements, management discussion, or detailed financial data. It is not a report but an announcement related to stock trading behavior and regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-09-27 Chinese
北京双鹭药业股份有限公司关于获得聚乙二醇化人粒细胞刺激因子注射液药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the receipt of a drug registration certificate for a specific pharmaceutical product. It includes detailed information about the drug, regulatory approval, and potential impact on the company. The document is relatively short (1394 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an official announcement about a regulatory approval rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.